Does Gleason pattern 5 influence the efficacy of enzalutamide against castration-resistant prostate cancer?
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.6_suppl.e598
Abstract: e598Background: In this study, we evaluated our cohort treated with enzalutamide retrospectively. We focused on Gleason pattern 5 prostate cancer which was very aggressive cancer and we investigated the difference in efficacy of enzalutamide between… read more here.
Keywords: efficacy enzalutamide; gleason; gleason pattern; prostate cancer ... See more keywords
Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.6_suppl.101
Abstract: 101Background: Enzalutamide is a potent androgen receptor (AR) inhibitor, targeting multiple steps in AR signaling. In recent years, the EMA and FDA approved enzalutamide for the management of adul... read more here.
Keywords: analysis nma; network meta; meta analysis; efficacy enzalutamide ... See more keywords
Efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with de novo (M1) metastatic hormone-sensitive prostate cancer (mHSPC) versus progression to mHSPC (M0): Post hoc analysis of the phase III ARCHES trial.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.6_suppl.102
Abstract: 102Background: In ARCHES (NCT02677896) ENZA + ADT reduced the risk of radiographic progression-free survival (rPFS) events, primary endpoint, and improved key secondary endpoints vs PBO + ADT in me... read more here.
Keywords: progression; efficacy enzalutamide; enza plus; mhspc ... See more keywords